Medtronic Announces Approval of Enlite® Sensor for iPro®2 Professional Continuous Glucose Monitoring System in the U.S.
September 01 2016 - 9:00AM
iPro2 Professional
CGM with Enlite Provides Critical Link Between Glucose Variability
and Lifestyle for Improved Diabetes Control
DUBLIN - Sept. 1, 2016 -
Medtronic plc (NYSE:MDT), the global leader in medical technology,
today announced the FDA approval of the Enlitesensor for use with
iPro2 Professional Continuous Glucose Monitoring (CGM) system, a
market-leading CGM system that enables healthcare providers to
obtain a more complete picture of glucose control for the diabetes
patients they treat. The Enlite sensor is a disposable glucose
sensor that can be worn up to six days and provides better
comfort.
Like a holter monitor for cardiovascular care, the
iPro2 Professional CGM system records a patient's glucose levels 24
hours a day for up to six days. Used intermittently, the iPro2
system provides physicians with insights into how the nutrition
plan, medication regimen and daily activities affect glucose levels
of people with diabetes, enabling them to know more about their
patients' glucose profile in less time and helping them to make
more informed decisions regarding diabetes management. Sharing
advanced insights enables patients to understand the relationship
between their glucose levels and lifestyle choices. In addition,
the iPro2 system delivers decision support for diabetes care
providers through an algorithm-based, one-page Pattern Snapshot
report that enhances their ability to quickly identify and address
key problem areas.
"We fundamentally believe that to improve outcomes
for people with diabetes, physicians need advanced insights to
optimize therapy and people with diabetes need to understand the
context behind glucose fluctuations to drive behavior change," said
Laura Stoltenberg, vice president and general manager,
Non-Intensive Diabetes Therapies at Medtronic. "Our focus is to
continuously enhance our professional CGM solutions and improve
patient and physician experience by making the systems
easier-to-use through advancements such as the Enlite sensor and
our Pattern Snapshot report."
"Both physicians and people with diabetes need
easy-to-use systems which can provide actionable information. The
new Enlite sensor is easy to insert and comfortable to wear. Having
six days of patient data permits robust pattern analysis for more
accurate decision support, "said Robert Vigersky, M.D., medical
director, Non-Intensive Diabetes Therapies at Medtronic. "With the
insights and reports provided through professional CGM, patients
can be shown the factors that are driving glucose fluctuations, so
together with their doctor they can develop a plan to improve
glucose control."
About the iPro2 Professional CGM
system
iPro2 Professional CGM includes the Enlite sensor, a disposable
glucose sensor that delivers better comfort and is 69% smaller than
the previous Medtronic sensor. The iPro2 system also includes a
small data recorder, which automatically records glucose
information. Patients simply wear the small, lightweight, discreet,
and watertight device while going about their normal daily
activities before returning it to the clinician's office for
evaluation.
Recording glucose every five minutes, the CGM
system captures up to 288 measurements a day, revealing hidden high
glucose (hyperglycemia) and low glucose (hypoglycemia) fluctuations
that A1C and finger sticks can miss. Since the data is masked,
unbiased information can be gathered to inform therapy decisions.
The system is simple to start - there is no computer required for
set up and minimal patient training is required. The Enlite sensor
requires a shorter sensor start-up time significantly reducing the
amount of clinical staff time needed to implement the
evaluation.
About the Diabetes Group at
Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to transform
diabetes care by expanding access, integrating care and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 88,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
Contacts:
Pamela Reese
Public Relations
+1-818-576-3398
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024